Eli Lilly’s Jaypirca succeeds in late-stage trial against Imbruvica of J&J and AbbVie Eli Lilly’s Jaypirca succeeds in late-stage trial against Imbruvica of J&J and AbbVie Post Contentlly, jnj, abbvRead More You might also be interested in reading Danaos proposes $500M senior notes offering. July 29, 2025 In Mainstream ← Previous post Next post →